, announced the launch of OptiLIFT , a new, proprietary Dynamic Muscle Stimulation technology (DMSt) for toning facial muscles to address lower lid laxity and impaired blinking without the need for surgery
ISBN 978-0-309-05292-4
Phase 2 Trial Design Participants: 338 adults with obesity (BMI 30) or overweight with comorbidities (BMI 27), without diabetes Duration: 48 weeks Dosing groups: Placebo, 1mg, 4mg, 8mg, or 12mg weekly (with gradual dose escalation over 20-24 weeks) Primary endpoint: Percentage change in body weight from baseline Beyond Weight Loss: Metabolic Improvements Beyond weight loss, the 12mg dose also improved several cardiometabolic markers: Blood pressure: Systolic BP decreased by 7.4 mmHg (clinically significant reduction) Lipids: Triglycerides fell 30%, HDL cholesterol increased 8% Glucose control: HbA1c decreased 0.4% even in participants without diabetes Liver health: Markers of fatty liver disease (ALT, AST) improved significantly Inflammation: C-reactive protein (CRP) decreased, indicating reduced systemic inflammation What this means: Retatrutide appears to improve the metabolic dysfunction behind obesity-related diseases, not just the weight itself
Kuipers, J., Jahn, K., Raphael, B
Kims analysis was done before the FDA approved GLP-1 drugs for chronic kidney disease, potentially sparing people from progressing to end-stage renal disease
